Abstract Number: 2367 • 2018 ACR/ARHP Annual Meeting
Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)
Background/Purpose: Biosimilars represent major potential savings while preserving treatment quality. However, few data are known on how to address the switch from originator to biosimilar…Abstract Number: 2368 • 2018 ACR/ARHP Annual Meeting
Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
Background/Purpose: Treatment choices in rheumatoid arthritis (RA) involve trade-offs in risks, benefits and other considerations such as dosing. Understanding patient preferences for these trade-offs is…Abstract Number: 2369 • 2018 ACR/ARHP Annual Meeting
Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
Background/Purpose: The offer of injectable MTX worldwide expanded during past few years with different types of enhanced devices such as prefilled syringes and autoinjector pens.…Abstract Number: 2370 • 2018 ACR/ARHP Annual Meeting
Physician and Patient Preferences for Treating SLE: Insights into the Choice of Intravenous Infusion and Subcutaneous Injection
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by diverse clinical manifestations, chronic inflammation, and significant morbidity that can be fatal1.…Abstract Number: 2371 • 2018 ACR/ARHP Annual Meeting
Use of Social Media Among Patients with Rheumatic Diseases
Background/Purpose: The impact of social media on individual or institutional communication and knowledge acquisition is non-negligible. Whether patients (pts) with rheumatic diseases share information about…Abstract Number: 2372 • 2018 ACR/ARHP Annual Meeting
Social Media Use for Health-Related Purposes By People with Rheumatic and Musculoskeletal Diseases – Results of a Global Survey
Background/Purpose: Smartphone applications and social media (SM) are increasingly used, transforming the way in which people communicate. Peer interaction, remote information access and community building…Abstract Number: 2373 • 2018 ACR/ARHP Annual Meeting
How Do Patients Describe Their “New Normal” in Systemic Lupus Erythematosus? Use of Probabilistic Topic Modelling to Characterize Patients’ Experiences Recorded in an Online Health Community
Background/Purpose: Patients living with systemic lupus erythematosus (SLE) must typically adapt to altered quality of life and tailor coping mechanisms (e.g. non-pharmacological interventions) to address…Abstract Number: 2374 • 2018 ACR/ARHP Annual Meeting
Flare Warnings: People with Rheumatoid Arthritis’ Perceptions of Their Flares
Background/Purpose: Flares are exacerbations of rheumatoid arthritis (RA) symptoms of sufficient intensity to require some change in treatment. Even when well-managed, more than half of…Abstract Number: 2375 • 2018 ACR/ARHP Annual Meeting
When Are People Receptive to Self Management Education Information, and What Information Appeals to Them? : An Analysis of Digital Data
Background/Purpose: CDC pilot-tested a marketing campaign to promote self-management education (SME) as a chronic disease management strategy. The campaign targets adults ages 45-75 with…Abstract Number: 2376 • 2018 ACR/ARHP Annual Meeting
Something for Us: Client Perspectives on Lupus Self-Management Programming Using the 5-a Behavior Change Model
Background/Purpose: Systemic lupus erythematosus is the most common and most severe form of lupus involving multiple body systems including the blood, muscles, joints, organs and…Abstract Number: 2377 • 2018 ACR/ARHP Annual Meeting
Body Image in Rheumatic Diseases: A Systematic Review
Background/Purpose: In health conditions that cause changes in appearance, especially in areas of the body that are highly visible and socially salient (e.g., face and…Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…Abstract Number: 2379 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Tocilizumab (TCZ) administered intravenously (IV) was shown to improve the signs and symptoms of polyarticular (p)JIA and systemic (s)JIA.1,2 An ongoing 3-year, long-term extension…Abstract Number: 2380 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Background/Purpose: Adalimumab (ADA) has been approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with long-term use often required to maintain disease control. The…Abstract Number: 2381 • 2018 ACR/ARHP Annual Meeting
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years…
ACR Meeting Abstracts